Diabetic nephropathy, also known as diabetic kidney disease, is one of the major diabetes complications and the leading cause of end-stage renal failure worldwide. Researchers from the School of Medicine and Health Sciences, Monash University, Malaysia conducted a randomized, double-blinded, placebo-controlled trial to investigate the effect of EVNol SupraBio, a supplement derived from Malaysian certified sustainable palm oil, on this condition. The study1 was published in the high-impact journal, Nutrient.
In general, kidney damage rarely happens in the first 10 years of diabetes. Kidney failure usually happens 15 to 25 years after the first symptoms of diabetes. Since diabetic nephropathy takes many years to develop, 45 patients with type 2 diabetes for an average of 18.5 years were selected for this study. Their microalbuminuria-positive result was ensured to be due to diabetic nephropathy alone (microalbuminuria is an early sign for kidney disease). They were randomly divided into 2 groups:
- Placebo group
- Intervention group receiving EVNol SupraBio
The blood serum of the patients was measured at baseline and after a short 8-week supplementation of either 400 mg/day EVNol SupraBio or placebo.
EVNol SupraBio bio-enhanced full-spectrum palm tocotrienol complex significantly reduced serum creatinine levels hence potentially averting the progression of renal impairment among the diabetic nephropathy patients.
No significant changes were observed in the level of HbA1c, serum AGE, sRAGE, Nε-CML and Cystatin C in the diabetic nephropathy patients in this study. This was opposite a previous study2 which showed that supplementation of EVNol SupraBio significantly reduced the aforementioned biomarkers on newly-induced diabetic rats. As per the researchers, the lack of significant effects observed in this study could be due to the long duration of diabetes among the patients (average 18.5 years), causing a long-term and difficult-to-reverse accumulation of these biomarkers in the body. This might have hindered the reduction and led the researchers to recommend a longer supplementation time for the tocotrienol to take effect.
Nevertheless, supplementation of EVNol SupraBio – a bioenhanced full-spectrum palm tocotrienol complex derived from certified sustainable Malaysian palm oil – significantly reduced serum creatinine compared to placebo. Therefore, the researchers concluded that EVNol SupraBio may be useful in addition to the current treatment for diabetic nephropathy.
ExcelVite Nutritionist Diyanah Roslan explains, “Tocotrienols have been proven to have 40 to 60 times more potent antioxidant activity compared to tocopherols and have superior anti-inflammatory, neuro-protective and cardio-protective properties. However, the reno-protective effect of tocotrienol in type 2 diabetes patient is currently limited and we are glad the researchers choose EVNol SupraBio to investigate the effect of tocotrienols in delaying diabetic nephropathy.”
ExcelVite Business Development Manager Bryan See added, “The number of people affected by diabetes continues to increase by the year, and it is vital to search for the right remedy to help delay diabetic complications, such as diabetic nephropathy. We are glad this study demonstrates the efficacy of EVNol SupraBio in reducing creatinine level specifically, which potentially could slow down the progression of diabetic nephropathy.”
- Suzanne May Quinn Tan, Yilynn Chiew, Badariah Ahmad and Khalid Abdul Kadir. (2018). Tocotrienol-rich vitamin E from palm oil (Tocovid) and its effects in diabetes and diabetic nephropathy: A pilot phase II clinical trial. Nutrients, 10(9). doi:10.3390/nu10091315.
- Cheng HS, et al. (2017). The ameliorative effects of a tocotrienol-rich fraction on the AGE-RAGE axis and hypertension in high-fat-diet-fed rats with metabolic syndrome. Nutrients, 9(9). doi:10.3390/nu9090984.
Disclaimer: The statements in the above article have not been evaluated by the Food and Drug Administration. They are not intended to diagnose, treat, cure or prevent any disease.